We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Image: Complement C7 was identified through multi-omics analysis, validated across MASLD cohorts, localized to hepatic stellate cell-rich fibrotic regions, and linked to extracellular matrix remodeling. (Image Credit: Dr. Takefumi Kimura from Shinshu University, Japan)

Multi-Omics Study Identifies Blood Marker for MASLD Progression

Researchers identify a blood-based marker that stratifies liver fibrosis and predicts future liver-related events in MASLD. More...
12 Oct 2026
Image: WashU Medicine researchers have found that a ratio between two immune cell types can reveal whether someone stays healthy or may face a higher risk of future disease. They found that having more granzyme K-producing white blood cells tipped the scale toward healthy aging, while having more granzyme B-producing cells was associated with chronic disease and even death. (Photo courtesy of Sara Moser/WashU Medicine)

Blood-Based Immune Aging Map Could Help Spot Disease Risk Earlier

Researchers identify an immune cell marker that gauges immune aging and predicts 10-year mortality and disease risk. More...
12 Oct 2026
Image: Laboratory specialists and clinicians from 48 countries participated in this survey. Countries are indicated in red. (Omosule, Catherine L., Lang, Tim, Geaghan, Sharon M., et al. Mapping pediatric cardiac troponin testing worldwide: results from the IFCC survey on emerging applications, standardization needs and access. Chemistry and Laboratory Medicine (CCLM), 2026. https://doi.org/10.1515/cclm-2026-0711)

Global Survey Finds Pediatric Troponin Testing Lacks Consistent Reference Intervals

New data reveal lack of pediatric troponin reference intervals, hindering interpretation and prompting development of standards. More...
12 Oct 2026
Image: The AidaBREAST assay integrates multimodal data to provide patient-specific 10-year recurrence risk and individualized predictions of radiation therapy benefit (photo courtesy of PreludeDx)

Validated Test Predicts Recurrence Risk and Radiation Benefit in Early-Stage Breast Cancer

A new multi-omic AI test predicts 10-year locoregional recurrence and radiation benefit in early-stage breast cancer. More...
12 Oct 2026
Image: Natera\'s MCED assay analyzes cell-free DNA in blood to screen for multiple cancers (Image Credit: Adobe Stock)

Multi-Cancer Screening Blood Test Gains FDA Breakthrough Designation

Natera’s  multi-cancer early detection (MCED) assay has received Breakthrough Device designation from the FDA. More...
12 Oct 2026
Image: The European CE marking represents the third CDx approval for ETCAMAH and the 31st CDx approval for Guardant Health (Photo courtesy of Guardant Health)

European Approval Expands Liquid Biopsy Use in Advanced Breast Cancer Testing

Guardant Health’s Guardant360 CDx has received CE marking as a companion diagnostic for AstraZeneca’s ETCAMAH. More...
12 Oct 2026
DB function failed with error number 0

AI Tool Predicts Long-Term Cardiovascular Risk from Sleep Study ECG

More...
11 Oct 2026
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Immunofluorescence Analyzer
IFA System
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Copyright © 2000-2026 Globetech Media. All rights reserved.